Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024

6/28/24 11:32:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $DNTH alert in real time by email

Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.

Get the next $DNTH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DNTH

Date	Price Target	Rating	Analyst
10/3/2024	$48.00	Outperform	Oppenheimer
7/26/2024	$58.00	Outperform	Robert W. Baird
6/27/2024		Overweight	Cantor Fitzgerald
5/16/2024	$40.00	Buy	H.C. Wainwright
2/15/2024	$44.00	Buy	Stifel
12/26/2023	$22.00	Buy	Jefferies
11/22/2023	$23.00	Outperform	Wedbush
10/30/2023	$45.00	Buy	Guggenheim

More analyst ratings

$DNTH
Press Releases

Fastest customizable press release news feed in the world

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 Approximately $343 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
11/7/24 4:01:00 PM ET
$DNTH
Biotechnology: Pharmaceutical Preparations
Health Care
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 1
11/4/24 7:00:00 AM ET
$DNTH
Biotechnology: Pharmaceutical Preparations
Health Care
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for p
10/15/24 7:00:00 AM ET
$DNTH
Biotechnology: Pharmaceutical Preparations
Health Care

Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024

Chat with this insight

Recent Analyst Ratings for
$DNTH

$DNTH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

SEC Form SC 13G filed by Dianthus Therapeutics Inc.

$DNTH
SEC Filings

SEC Form 10-Q filed by Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form RW filed by Dianthus Therapeutics Inc.

$DNTH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Fairmount Funds Management Llc disposed of 62,146 shares (SEC Form 4)

SEC Form 4 filed by Director Romano Steven J.

SEC Form 3 filed by new insider Romano Steven J.

$DNTH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Dianthus Therapeutics with a new price target

Robert W. Baird initiated coverage on Dianthus Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Dianthus Therapeutics

$DNTH
Press Releases

Fastest customizable press release news feed in the world

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

$DNTH
Leadership Updates

Live Leadership Updates

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

$DNTH
Market Insights

Live Market Insights

Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024

Dianthus Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.

Cantor Fitzgerald Initiates Coverage On Dianthus Therapeutics with Overweight Rating

Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024

Chat with this insight

Recent Analyst Ratings for $DNTH

$DNTH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Dianthus Therapeutics Inc.

SEC Form SC 13G filed by Dianthus Therapeutics Inc.

$DNTH SEC Filings

SEC Form 10-Q filed by Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form RW filed by Dianthus Therapeutics Inc.

$DNTH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Fairmount Funds Management Llc disposed of 62,146 shares (SEC Form 4)

SEC Form 4 filed by Director Romano Steven J.

SEC Form 3 filed by new insider Romano Steven J.

$DNTH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Dianthus Therapeutics with a new price target

Robert W. Baird initiated coverage on Dianthus Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Dianthus Therapeutics

$DNTH Press Releases

Fastest customizable press release news feed in the world

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

$DNTH Leadership Updates

Live Leadership Updates

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

$DNTH Market Insights

Live Market Insights

Dianthus Therapeutics Announces Two Poster Presentations For DNTH103 At The 10th Congress Of The European Academy Of Neurology June 29-July 2, 2024

Dianthus Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating.

Cantor Fitzgerald Initiates Coverage On Dianthus Therapeutics with Overweight Rating

Recent Analyst Ratings for
$DNTH

$DNTH
Large Ownership Changes

$DNTH
SEC Filings

$DNTH
Insider Trading

$DNTH
Analyst Ratings

$DNTH
Press Releases

$DNTH
Leadership Updates

$DNTH
Market Insights